• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery.

作者信息

Selby Luke V, Ejaz Aslam, Brethauer Stacy A, Pawlik Timothy M

机构信息

Department of Surgery, Divisions of Surgical Oncology and GI/General Surgery, The Ohio State University Medical Center, Columbus, OH, USA.

出版信息

Expert Opin Investig Drugs. 2020 Feb;29(2):107-110. doi: 10.1080/13543784.2020.1721457. Epub 2020 Jan 27.

DOI:10.1080/13543784.2020.1721457
PMID:31986920
Abstract
摘要

相似文献

1
Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery.脂肪肝疾病与原发性肝癌：发病机制、新兴疗法及减重手术的作用
Expert Opin Investig Drugs. 2020 Feb;29(2):107-110. doi: 10.1080/13543784.2020.1721457. Epub 2020 Jan 27.
2
HSCRP as surrogate marker in predicting long term effect of bariatric surgery on resolution of non-alcoholic steatohepatitis.hsCRP 作为预测减重手术对非酒精性脂肪性肝炎缓解的长期效果的替代标志物。
Asian J Surg. 2019 Jan;42(1):203-208. doi: 10.1016/j.asjsur.2018.04.010. Epub 2018 May 24.
3
The Role Bariatric Surgery and Endobariatric Therapies in Nonalcoholic Steatohepatitis.减重手术和内镜减重治疗在非酒精性脂肪性肝炎中的作用
Clin Liver Dis. 2023 May;27(2):413-427. doi: 10.1016/j.cld.2023.01.009. Epub 2023 Feb 26.
4
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.肝硬化的挑战与管理：非酒精性脂肪性肝病和非酒精性脂肪性肝炎所致肝硬化患者治疗中的实际问题
Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6.
5
Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.肥胖症手术可减轻病态肥胖患者非酒精性脂肪性肝炎的特征。
Gastroenterology. 2015 Aug;149(2):379-88; quiz e15-6. doi: 10.1053/j.gastro.2015.04.014. Epub 2015 Apr 25.
6
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes.非酒精性脂肪性肝病综述：诊断、治疗和结局。
Clin Gastroenterol Hepatol. 2015 Nov;13(12):2062-70. doi: 10.1016/j.cgh.2015.07.029. Epub 2015 Jul 27.
7
Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score).基于标准化 NAS（非酒精性脂肪性肝病活动评分），肥胖症患者在接受减重手术后其非酒精性脂肪性肝病的组织学改善。
Surg Obes Relat Dis. 2018 Oct;14(10):1607-1616. doi: 10.1016/j.soard.2018.07.012. Epub 2018 Jul 24.
8
Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease.减肥、饮食、运动和减重手术对非酒精性脂肪性肝病的影响。
Clin Liver Dis. 2016 May;20(2):339-50. doi: 10.1016/j.cld.2015.10.008. Epub 2016 Feb 17.
9
Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.非酒精性脂肪性肝病和非酒精性脂肪性肝炎：药物治疗的成功开发将取决于转化研究。
Digestion. 2019;100(2):79-85. doi: 10.1159/000493259. Epub 2018 Dec 7.
10
The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis.代谢手术对脂肪肝疾病和非酒精性脂肪性肝炎的影响。
Surg Clin North Am. 2016 Aug;96(4):703-15. doi: 10.1016/j.suc.2016.03.008.

引用本文的文献

1
The effect of continuous infusion chemotherapy through femoral artery catheterization on GP73, AFP-L3, and safety efficacy in liver cancer patients.经股动脉插管持续输注化疗对肝癌患者GP73、甲胎蛋白异质体L3及安全性疗效的影响
Clin Exp Med. 2025 May 10;25(1):148. doi: 10.1007/s10238-025-01560-y.
2
Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.评估索拉非尼在晚期肝癌靶向治疗中的疾病控制率和安全性。
World J Surg Oncol. 2024 Apr 12;22(1):93. doi: 10.1186/s12957-024-03364-y.
3
Association of County-Level Food Deserts and Food Swamps with Hepatopancreatobiliary Cancer Outcomes.
县级食物荒漠和食物沼泽与肝胆胰癌症结局的关联。
J Gastrointest Surg. 2023 Dec;27(12):2771-2779. doi: 10.1007/s11605-023-05879-3. Epub 2023 Nov 8.
4
Effect of Pioglitazone on Nonalcoholic Fatty Liver Disease in Morbid Obese Patients; a Randomized Controlled Trial.吡格列酮对病态肥胖患者非酒精性脂肪性肝病的影响；一项随机对照试验。
Adv Biomed Res. 2023 Feb 25;12:27. doi: 10.4103/abr.abr_354_21. eCollection 2023.
5
The pathogenesis of liver cancer and the therapeutic potential of bioactive substances.肝癌的发病机制及生物活性物质的治疗潜力。
Front Pharmacol. 2022 Oct 5;13:1029601. doi: 10.3389/fphar.2022.1029601. eCollection 2022.
6
Construction and validation of a prognostic marker and risk model for HCC ultrasound therapy combined with WGCNA identification.基于加权基因共表达网络分析（WGCNA）鉴定构建并验证肝癌超声治疗的预后标志物及风险模型
Front Genet. 2022 Oct 3;13:1017551. doi: 10.3389/fgene.2022.1017551. eCollection 2022.